Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on January 5, 2024. The Company is a biotechnology firm focused on researching treatments, prevention methods, and cures for Alzheimer's Disease. The report covers events occurring on January 4, 2024.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
The primary material change reported is the appointment of Milton C. Ault, III as a director and Vice Chairman of the Board, effective January 4, 2024. Mr. Ault is the founder of the Company and previously served as Chairman Emeritus and consultant. Concurrent with this appointment, his prior consulting agreement and associated compensation were terminated.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations or future performance. Regarding compensation, Mr. Ault will be compensated in accordance with the Company's standard Board policies, as previously disclosed in the Form 10-K for the fiscal year ended April 30, 2023. The filing confirms there are no reportable related party transactions involving Mr. Ault under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Mr. Ault's new role as Vice Chairman and Director is effective January 4, 2024.
- Mr. Ault's previous consulting agreement was terminated upon his appointment to the Board.
- Mr. Ault holds significant leadership roles in other public entities, including Executive Chairman of Ault Alliance, Inc. (NYSE American) and Chairman of Ault Disruptive Technologies Corporation (NYSE).
- Mr. Ault's compensation will follow standard Board policies disclosed in the prior fiscal year's 10-K.
- No financial data or operational metrics are provided in this specific filing.